The effects of bortezomib on the systemic CAEBV xenograft model. The xenograft model of systemic CAEBV was generated using NOG mice. Mice were injected intraperitoneally with 300 μL of PBS, or 1.67 mg/kg bortezomib in 300 μL of PBS twice a week for 3 weeks. (A-B) PBS and bortezomib were administered to 11 mice for each. The EBV-DNA load of PB and the body weight were monitored weekly. *P < .05. (C-D) The concentration of cytokines in the serum was measured every week among 3 mice established by injecting the PBMCs of the CD4-3 patient. The data represent the mean plus or minus SD of each independent experiments. (E) Representative images of hematoxylin/eosin (HE) staining and EBER ISH are shown after 3 weeks of treatment with bortezomib or PBS in the mice established by injecting PBMCs of the CD4-3 patient. Original magnification ×400. (F) The survival curve of the bortezomib-treated mice (n = 40: 20 CD4 cell type, 20 CD56 cell types) and the PBS-treated mice (n = 40: 20 CD4 cell type, 20 CD56 cell types) was analyzed by the log-rank test.